• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration

    Catalent Acquires Delphi Genetics

    Almac Group Completes $7M R&D Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre

    AARDEX Group Partners with Pill Connect

    Phillips-Medsize and Subcuject Collaborate
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Aphena Pharma Solutions

    Almac Group

    test company saurabh

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Alcami

    Emergent BioSolutions

    Reed-Lane

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Rapid Delivery of Medical Countermeasures Amid Pandemic

    Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines

    Rapid Delivery of Medical Countermeasures Amid Pandemic
    Photo courtesy of iBio
    Rapid Delivery of Medical Countermeasures Amid Pandemic
    Photo courtesy of iBio
    Kristin Brooks, Managing Editor, Contract Pharma05.05.20
    Immeasurable efforts are underway to develop treatments and vaccines to address the COVID-19 pandemic. Numerous discovery methods and technologies are currently being explored in clinical trials such as DNA and RNA-based vaccine candidates, adjuvant platform technologies, recombinant nanoparticles, and monoclonal antibodies, to name a few. As promising therapies begin to emerge, they’ll need to be rapidly scaled up for trials and potential commercialization, which is not without its challenges in a pandemic setting.

    iBio, Inc., a biologics CMO and biotechnology company, is working to develop vaccine candidates to prevent infection from the SARS-CoV-2 virus that causes COVID-19 disease. iBio created its SARS-CoV-2 Virus-Like Particle (VLP)-based constructs in just a few weeks using its FastPharming System to produce the nanoparticles in, and purify them from, plants. The manufacturing platform allows for rapid development of research quantities of product, as well as high-quality material that is readily scalable for producing doses for clinical trials and commercial use.

    Originally built in 2010 with funding from the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense, iBio’s FastPharming Facility was part of the “Blue Angel” initiative to establish facilities capable of rapid delivery of medical countermeasures in response to a disease pandemic. The factory is equipped with automated hydroponics and vertical farming systems for the production of a wide array of biological medicines using a relative of the tobacco plant as the “bioreactor.”

    Contract Pharma spoke with Robert L. Erwin, president of iBio about the manufacturing platform and potential timeline for the delivery of COVID-19 medical countermeasures.

    Contract Pharma (CP): Please describe iBIO’s manufacturing platform being leveraged to develop vaccine candidates.

    Robert Erwin:
    iBio’s FastPharming System uses plants as bioreactors, rather than traditional mammalian or microbial cell culture bioprocesses. The plant bioreactors are grown in a specially designed, optimized, and controlled indoor vertical farm environment employing large-scale hydroponics and LED lighting tuned for consistent growth. The gene encoding the specific protein of interest is cloned into a plant-specific expression vector and transfected into Agrobacterium tumifaciens. The expression vector housed within Agrobacterium is then delivered into the leaves of iBio’s proprietary Nicotiana benthamiana plants, which are close relatives of common tobacco plants, by a process called vacuum infiltration. After infiltration, the target protein is expressed in the leaves and, approximately one week later, high-throughput harvest of the leaves is followed by extraction of the target protein, purification, formulation into the desired final product, and appropriate fill/finish processes.

    Transient plant-based production significantly reduces the time and cost associated with: (i) the initial upstream setup and execution, (ii) production scale-up, and (iii) characterization and quality assessments compared with conventional bioproduction methods. As each plant serves as a standalone bioreactor, there is a very high degree of consistency between material produced at the research stage and commercial-scale production, and scaling to any level can be directly achieved by simply growing more plants. The FastPharming platform provides confidence that critical consistency is maintained under the accelerated timelines for vaccine and/or therapeutic development and manufacturing during a pandemic.

    CP: What development progress have you seen thus far and do you anticipate any specific challenges going forward?

    Erwin:
    iBio’s FastPharming Technology has been previously deployed for development, manufacture, and evaluation of vaccine candidates for viral and bacterial pathogens in clinical trials. That experience was rapidly put to use in January to design, express, and produce COVID-19 vaccine candidates. These candidates are undergoing additional development to select a lead candidate and formulation for extensive animal testing and initial human clinical evaluation. Based on existing data and experience, we do not anticipate manufacturing challenges, and we believe most safety questions can be addressed within a matter of weeks.

    CP: What are the major challenges conducting clinical trials during this pandemic?

    Erwin:
    There are a myriad of challenges to the manufacturing and clinical trial supply chain already occurring, with likely broader impacts that will continue to ripple across the industry. Efficient clinical trials require the coordination of supply of not only the experimental drugs, but also comparator drugs, ancillary supplies, and laboratory equipment. These are overlaid with proper clinical packaging, oversight of blinding, and the protection of patient data. Bottlenecks in supply chain links to any of the relevant supplies can potentially compromise a clinical trial, and shortages of even simple routine supplies––like surgical gloves and masks––have already manifested.

    Additionally, there are growing concerns about the risks of exposure of vulnerable, potentially immunocompromised patients to SARS-CoV-2 at traditional clinical trials centers, and as such the need for direct-to-patient (DTP) clinical trials models and associated services have become even more acute. Clinical trial logistics organizations are already being tested to secure the supply of existing DTP trials, and this will grow as more previously centralized trials transition into DTP models. Many clinical trials unrelated to COVID-19 have been delayed or even suspended within the last two weeks.

    CP: What is the potential timeline for the delivery of medical countermeasures in response to the COVID-19 pandemic?

    Erwin:
    Aside from protective equipment for healthcare workers, diagnostic tests, and critical care equipment, all of which have seen significant delivery shortfalls, there are still opportunities for government and industry partnerships, to speed the development, testing, and delivery of therapeutic and protective (i.e., vaccine) countermeasures to combat the COVID-19 pandemic.

    Some therapeutics can be repurposed from applications already approved by the FDA and are in clinical trials already, with mixed success to date. More promising experimental therapeutics are in various stages of early development, and the FDA has created accelerated review pathways to facilitate rapid initiation of clinical trials. The timelines for delivery of promising experimental therapeutics depend on the rate at which patients are accrued to clinical trials, the efficacy and safety of the novel drugs, and the speed with which cGMP manufacturing capacity can be developed or accessed. The better of these new drug candidates are likely to be used in emergency treatment in parallel with careful evaluation of their safety and efficacy in patients who are not critically ill. Conditional FDA approvals, if supported by compelling clinical data, could occur as soon as this year.

    Vaccines represent a different challenge in that they must be safe enough to administer to healthy people who may or may not be at risk of infection. This requires careful, early clinical evaluation followed by more extensive testing in larger groups to assess the protective value of a new vaccine. The FDA has already selectively relaxed requirements for preclinical safety evaluation of vaccine candidates for SARS-CoV-2 prior to approving initiation of human clinical trials.

    iBio’s plant-based vaccine candidates combine two of the critical features required for rapid deployment. The first is a formulation that is likely to rapidly prove to be safe and effective, based on prior experience with plant-based VLPs tested against other targets and current knowledge of vaccine design alternatives intended to be effective in stimulation of a protective immune response. The second critical feature enabling rapid delivery of iBio’s vaccine countermeasure(s) is the combination of FastPharming technology with iBio’s cGMP manufacturing facility. Together, these are capable of assuring delivery of millions of doses of vaccine every month beginning immediately upon FDA approval, much faster than traditional approaches to manufacture of protein subunit vaccines. 

    Related Columns

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • A Potential “Marriage”

      A Potential “Marriage”

      Initiator companies and generics/CMOs working together.
      Emil W. Ciurczak, DoraMaxx Consulting 11.17.20

    • When Politics and Science Collide

      When Politics and Science Collide

      COVID-19 illustrates why science should always be a principal informer of politics to make better and smarter decisions.
      Ben Locwin, Contributing Editor 11.17.20


    • The Pandemic’s Become an Insurmountable Opportunity

      The Pandemic’s Become an Insurmountable Opportunity

      Every Cloud has a Silver Lining(?)
      Emil W. Ciurczak, Contributing Editor 10.14.20

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20

    • cGMP Manufacture
      Keys to Biotech Success

      Keys to Biotech Success

      Four steps emerging biotech companies can take to achieve success
      Thierry Cournez, Head of End-to-End Solutions, MilliporeSigma 06.04.20


    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Almost Like the Olympics:

      Almost Like the Olympics:

      “Smaller, Faster, Smarter”
      Emil W. Ciurczak, DoraMaxx Consulting 05.05.20

    • The Supply Chain House of Cards

      The Supply Chain House of Cards

      The COVID-19 pandemic exposes pressures on extended global supply chains
      Emil W. Ciurczak, DoraMaxx Consulting 04.01.20


    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Coronavirus 2020

      Coronavirus 2020

      What’s The Impact To The World and Industry?
      Ben Locwin, Contributing Editor 03.04.20

    • Supply Chain
      What We Have is Failure to Communicate

      What We Have is Failure to Communicate

      When it comes to implementing track and trace technology, why is Pharma dragging its feet?
      Emil W. Ciurczak, DoraMaxx Consulting 01.28.20


    • Vision: 2020

      Vision: 2020

      You have exactly 366 days in 2020 to bring your clarity of vision to reality.
      Ben Locwin 01.28.20

    • Solid Dosage/Creams/Ointments
      The “Greening” of Solid Dosage Form Manufacturing

      The “Greening” of Solid Dosage Form Manufacturing

      Going “green” can mean saving big bucks for pharma manufacturers.
      Emil W. Ciurczak, DoraMaxx Consulting 11.20.19

    • When Life Gives You Lemons…Raise Your Drug Prices

      When Life Gives You Lemons…Raise Your Drug Prices

      The hidden effect of economic models on global drug supply and shortages.
      Ben Locwin 11.20.19

    Trending
    • Century Therapeutics Significantly Expands Capabilities
    • Catalent Acquires Delphi Genetics
    • Sanofi And Translate Bio Expand Vaccine Collaboration
    • RotaChrom Technologies Partners With Cyclolab
    • Inside A Vaccine Trial
    Breaking News
    • Altasciences Contributes to Vibegron Approval
    • Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    • Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    • ACG Launches ACG Laboratories
    • Glatt and Aprecia Enter 3D-Printing Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    Hempel Launches Sustainability Framework: Futureproof
    ChemQuest Hires Rich Gibson
    New Increase in Kynar Fluoropolymer Capacities at Arkema's Chinese Site
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Terumo to Purchase Predictive Analytics Firm Health Outcomes Sciences
    Abiomed Leader Michael Minogue Named AdvaMed Board Chairman
    TransEnterix Changes Name to Asensus Surgical
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Altasciences Contributes to Vibegron Approval
    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Madison Reed Raises $52 Million in Financing Round
    The Estée Lauder Companies Closes Becca Cosmetics
    Afro Sheen Launches New Brand Initiatives
    Happi

    Latest Breaking News From Happi

    PBA Opposes House Bill 2325 in West Virginia
    J.R. Watkins Tackles Pain with New Lines
    RB Launches Vanish Miracle
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eaglewood Technologies debuts new anilox cleaning system
    INX International and VerifyMe sign supply agreement
    Soma partners with DTM Flexo Services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    H&V Announces Price Increase
    Fiber Bond VE3 Technology Inactivates SARS-CoV-2 in HVAC Filtration Systems
    Citizens Provides $325 Million Senior Credit Facility to Nice-Pak
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    NuVasive Nabs Simplify Medical for $150M
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Nexus Spine Implants for Use in Spinal Surgeries Become Available
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login